Outcomes of Simultaneous Pancreas and Kidney Transplantation With a High Level of Preformed Antibodies

H. Sharma, A. El-Bakry, V. Venkat, S. Papachristos, R. Dhanda, D. Van Dellen, T. Campbell, T. Augustine, R. Pararajasingam, A. Tavakoli, B. Forgacs.

Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.

Meeting: 2015 American Transplant Congress

Abstract number: C192

Keywords: Pancreas transplantation, Sensitization

Session Information

Session Name: Poster Session C: More Controversies in Pancreas Transplantation

Session Type: Poster Session

Date: Monday, May 4, 2015

Session Time: 5:30pm-6:30pm

Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

BACKGROUND:

There is paucity of data of outcomes of simultaneous pancreas and kidney transplantation in recipients with preformed antibodies. Newer induction agents have been used with variable success rates.

METHODS:

We analyzed the significance of high sensitization, defined based on the presence of high levels of preformed antibodies (cPRA >60%), on the outcomes of simultaneous pancreas and kidney (SPK) transplantation. We reviewed 273 SPK transplants performed at our center over last 10 years and identified 13 patients who met high sensitization criteria. All recipients had campath induction. Stats-direct 3 was used for statistical analysis.

RESULTS:

The 5-year graft survival was 69% (95% CI, 0.51-0.86) , the 5-year patient survival was 93% (95% CI, 0.74-0.96). (There were four pancreatic allograft failures within first three months of transplantation). There were no immunological causes of these allograft failures. The adjusted hazard ratio associated with the risk of allograft failure was 0.4. There were no statistically significant correlation between grafts function and age of recipient – p=0.91; peak antibody levels and biopsy proven acute rejection episodes p=0.68; peak antibody levels and delayed graft function p=0.93 on multiple regression model.

CONCLUSION:

Sensitization does not appear to have a significant negative impact on the survival and long-term outcomes of SPK transplant patients.

To cite this abstract in AMA style:

Sharma H, El-Bakry A, Venkat V, Papachristos S, Dhanda R, Dellen DVan, Campbell T, Augustine T, Pararajasingam R, Tavakoli A, Forgacs B. Outcomes of Simultaneous Pancreas and Kidney Transplantation With a High Level of Preformed Antibodies [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-simultaneous-pancreas-and-kidney-transplantation-with-a-high-level-of-preformed-antibodies/. Accessed May 13, 2025.

« Back to 2015 American Transplant Congress